W. L. Gore & Associates, Inc. (Gore) congratulates the REVISE research team for receiving the JVIR Editor’s Award for Outstanding Clinical Research Paper for 2019 from the Journal of Vascular and Interventional Radiology.

FLAGSTAFF, Ariz. (October 28, 2022) — W. L. Gore & Associates (Gore) today announced the first implants of its investigational GORE® VIAFORT Vascular Stent as part of the recently initiated GORE VIAFORT Device  Pivotal Clinical Study, (i.e., prospective, multicenter, non-randomized, single-arm study NCT05409976) for the treatment of inferior vena cava (IVC) occlusive disease with or without iliofemoral vein involvement. 

The Gore VBX FORWARD Clinical Study aims to compare the VBX Stent Graft primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease.

The Gore RELIEF study is evaluating the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) with the GORE® CARDIOFORM Septal Occluder for the relief of migraine headaches.

FLAGSTAFF, Ariz. (APRIL 12, 2022) — Gore Medical has received Breakthrough Device designation from the U.S. Food and Drug Administration for the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device). The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The TAMBE Device is the third Breakthrough Device in the company’s aortic endovascular portfolio to date, following the GORE® TAG® Thoracic Branch Endoprosthesis and the GORE® Ascending Stent Graft, two other investigational devices being developed.

First off-the-shelf solution for treatment of complex aneurysmal disease involving the visceral aorta.

FLAGSTAFF, Ariz. (March 11, 2021)— W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England Journal of Medicine (NEJM), highlighting the benefits of patent foramen ovale (PFO) closure. The extended follow-up data further supports the use of GORE CARDIOFORM Septal Occluder in long-term recurrent stroke prevention.

Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success^* with the GORE^® CARDIOFORM ASD Occluder, and consistent safety outcomes^† across a broad range of ASD anatomies,^‡,1,2 including patients with deficient retro-aortic rims.^§,2 View the published study here.